Showing 431-440 of 834 results for "".
- Aura Biosciences Appoints George Golumbeski, PhD, as Chairman of the Board of Directorshttps://modernod.com/news/aura-biosciences-appoints-george-golumbeski-phd-as-chairman-of-the-board-of-directors/2477212/Aura Biosciences announced the appointment of George Golumbeski, PhD, as Chairman of its Board of Directors. Dr. Golumbeski is a biopharmaceutical business leader with over 25 years of experience in the biotechnology industry. “George’s extensive experience will be invaluable to Aura as we
- Alon Harris, MS, PhD, Named 2025 Recipient of Robert Ritch Award for Innovation and Excellence in Glaucomahttps://modernod.com/news/alon-harris-named-2025-recipient-of-robert-ritch-award-for-innovation-and-excellence-in-glaucoma/2482778/Alon Harris, MS, PhD, FARVO, has been announced as the 2025 recipient of The Glaucoma Foundation’s (TGF) 'Robert Ritch Award for Innovation and Excellence in Glaucoma.' The award, established in 2008 and named after TGF founder Robert Ritch, MD, honor
- Aerie Pharmaceuticals Announces Appointment of Michelle Senchyna, PhD, as Vice President, Clinical Development and Medical Affairshttps://modernod.com/news/aerie-pharmaceuticals-announces-appointment-of-michelle-senchyna-phd-as-vice-president-clinical-development-and-medical-affairs/2477271/Aerie Pharmaceuticals announced the appointment of Michelle Senchyna, PhD, as Vice President, Clinical Development and Medical Affairs, reporting to David A. Hollander, MD, MBA, Aerie’s Chief Research & Development Officer. Dr. Senchyna will lead and direct the clinical development and
- Humonix Biosciences Appoints Karen Torrejon, PhD, as New CEOhttps://modernod.com/news/humonix-biosciences-appoints-karen-torrejon-phd-as-new-ceo/2482275/Humonix Biosciences announced the appointment of Karen Torrejon, PhD, as the new Chief Executive Officer. Dr. Torrejon, who originally founded the company in 2014, will now be leading the company as it transitions into a broader, science-driven platform. Humonix’s platform has bee
- Kaustabh Ghosh, PhD, Recognized With Catalyst Award for Innovative AMD Researchhttps://modernod.com/news/dr-kaustabh-ghosh-recognized-with-catalyst-award-for-innovative-amd-research/2481657/Doheny Eye Institute announced that Kaustabh Ghosh, PhD, was recently recognized by non-profits Research to Prevent Blindness (RPD) and the International Retinal Research Foundation (IRRF) with the Catalyst Award for innovative approaches for age-related macular degeneration (AMD). 
- Opus Genetics Appoints Ben Yerxa, PhD, as Permanent Chief Executive Officerhttps://modernod.com/news/opus-genetics-appoints-ben-yerxa-phd-as-permanent-chief-executive-officer/2480923/Opus Genetics announced the appointment of Ben Yerxa, PhD, as Chief Executive Officer. Dr. Yerxa previously served as acting CEO of Opus, in addition to former roles as CEO of the Foundation Fighting Blindness and the Retinal Degeneration (RD) Fund, the venture arm of th
- Dopavision Appoints Mark S. Wuttke, PhD, as Chief Executive Officerhttps://modernod.com/news/dopavision-appoints-mark-s-wuttke-phd-as-chief-executive-officer/2480881/Dopavision announced that Mark S. Wuttke, PhD, has been appointed as the company´s Chief Executive Officer. He succeeds Dopavision´s co-founder and previous Managing Director Stefan Zundel, who will remain on Dopavision´s advisory board and continue to advise the company.</
- Aura Biosciences Names Mark De Rosch, PhD, Chief Operating Officerhttps://modernod.com/news/aura-biosciences-names-mark-de-rosch-phd-chief-operating-officer/2479008/Aura Biosciences announced the appointment of Mark De Rosch, PhD, as Chief Operating Officer. In his role, he will be responsible for leading Aura’s global operations and regulatory strategy. Dr. De Rosch brings to Aura more than 30 years of experience in leading global regulatory and deve
- Neurophth Therapeutics Appoints Qiutang Li, PhD, as Chief Scientific Officerhttps://modernod.com/news/neurophth-therapeutics-appoints-qiutang-li-phd-as-chief-scientific-officer/2478800/Wuhan Neurophth Biotechnology, a developer of AAV-delivered gene therapies for the treatment of ocular diseases, announced the appointment of Qiutang Li, PhD, as Chief Scientific Officer. She will be mainly responsible for the company’s global R&D, IND portfolio strategy, and the establ
- Iveric bio Appoints Abraham Scaria, PhD, as Chief Scientific Officerhttps://modernod.com/news/iveric-bio-appoints-abraham-scaria-phd-as-chief-scientific-officer/2477050/Iveric bio announced the appointment of Abraham Scaria, PhD, to the position of Chief Scientific Officer, effective October 29, 2019. Dr. Scaria will lead the company’s research and preclinical gene therapy activities. Dr. Scaria’s extensive experience includes positions at Genzyme, Sanofi, and m